Study Title,Interventions (Drugs),SMILES,Type (C/I),Location,Remarks
Hydroxychloroquine to Prevent Covid19 Pneumonia (ALBERTA HOPE-Covid19),Hydroxychloroquine,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,C,"University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada",
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,angiotensin-converting enzyme 2,CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N,C,"GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,angiotensin-converting enzyme 2,CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N,I,"GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O,C,"CHU d'Angers, Angers, France, AP-HP - Hôpital Bichat, Paris, France, CHU de Saint-Etienne,Saint-Étienne, France",
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Lopinavir,CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O,I,"CHU d'Angers, Angers, France, AP-HP - Hôpital Bichat, Paris, France, CHU de Saint-Etienne,Saint-Étienne, France",
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,C,"CHU d'Angers, Angers, France, AP-HP - Hôpital Bichat, Paris, France, CHU de Saint-Etienne,Saint-Étienne, France",
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,ritonavir,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,I,"CHU d'Angers, Angers, France, AP-HP - Hôpital Bichat, Paris, France, CHU de Saint-Etienne,Saint-Étienne, France",
"Efficacy of Addition of Naproxen in the Treatment of Critically 
Ill Patients Hospitalized for COVID-19 Infection",Naproxen,CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,C,,
"Efficacy of Addition of Naproxen in the Treatment of Critically 
Ill Patients Hospitalized for COVID-19 Infection",Naproxen,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,I,,
"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With 
Suspected or Confirmed COVID-19",Azithromycin,CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,C,"Intermountain Medical Center
 Murray, Utah, United States
 University of Utah
 Salt Lake City, Utah, United States",
"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With 
Suspected or Confirmed COVID-19",Azithromycin,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,I,"Intermountain Medical Center
 Murray, Utah, United States
 University of Utah
 Salt Lake City, Utah, United States",
Treatment of COVID-19 Patients With Anti-interleukin Drugs,Anakinra,CC(C)(C)C(=O)OCON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C=C)C(=O)O,C,"AZ Sint-Jan Brugge
 Brugge, Belgium
 University Hospital Saint-Pierre
 Brussels, Belgium
 Erasmus University Hospital
 Brussels, Belgium",
"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) 
in Hospitalized Patients",Baricitinib,CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,C,,
"Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized 
Patients With COVID19 Pneumonia",Methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C,"Hospital Clínic de Barcelona
 Barcelona, Spain",
"Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized 
Patients With COVID19 Pneumonia",Methylprednisolone,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,I,"Hospital Clínic de Barcelona
 Barcelona, Spain",
"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in 
Treatment of COVID-19",Levamisole,C1CSC2=NC(CN21)C3=CC=CC=C3,C,,
"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in 
Treatment of COVID-19",Levamisole,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,I,,
"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in 
Treatment of COVID-19",Budesonide,CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C,C,,
"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in 
Treatment of COVID-19",Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,I,,
"Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) 
in Participants With Moderate Coronavirus Disease (COVID-19)
 Compared to Standard of Care Treatment",Remdesivir,CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,C,"Kaiser Permanente Los Angeles Medical Center, 
3340 E. La Palma Avenue
 Anaheim, California, United States",
"Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) 
in Participants With Moderate Coronavirus Disease (COVID-19)
 Compared to Standard of Care Treatment",Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,I,"Kaiser Permanente Los Angeles Medical Center, 
3340 E. La Palma Avenue
 Anaheim, California, United States",
Tetrandrine Tablets Used in the Treatment of COVID-19,Tetrandrine,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,C,"Tetrandrine Tablets
 Jinhua, Zhejiang, China",
Tetrandrine Tablets Used in the Treatment of COVID-19,Tetrandrine,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,I,"Tetrandrine Tablets
 Jinhua, Zhejiang, China",
The Vietnam Chloroquine Treatment on COVID-19,Chloroquine phosphate,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O,C,"National Hospital for Tropical Diseases
 Hanoi, Vietnam",
"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate
 New Coronavirus (COVID-19) Pneumonia",thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C,,
"Efficacy of Dexamethasone Treatment for Patients With ARDS
 Caused by COVID-19",Dexamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,C,"Department of Anesthesia, Hospital 
Universitario de CrucesBarakaldo, Vizcaya, Spain",
"Efficacy of Dexamethasone Treatment for Patients With ARDS
 Caused by COVID-19",Dexamethasone,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,I,"Department of Anesthesia, Hospital 
Universitario de CrucesBarakaldo, Vizcaya, Spain",
Fingolimod in COVID-19,Fingolimod,CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N,C,"Wan-Jin Chen
 Fuzhou, China",
"The GReek Study in the Effects of Colchicine in Covid-19 
cOmplications Prevention",Colchicine,CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,C,,
"The GReek Study in the Effects of Colchicine in Covid-19 
cOmplications Prevention",Colchicine,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,I,,
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,Ruxolitinib,C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,C,"Princess Margaret Cancer Centre
 Toronto, Ontario, Canada",
Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia,Ruxolitinib,C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3,I,"Princess Margaret Cancer Centre
 Toronto, Ontario, Canada",
Immunoregulatory Therapy for 2019-nCoV,Thymosin,CCC(C)C(C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CS)N,C,,
Immunoregulatory Therapy for 2019-nCoV,Thymosin,CC[C@H](C)[C@H](C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CO)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CS)N,I,,
"Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets
 Combined With Standard Treatment/ Standard Treatment in Patients With 
Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",Bromhexine Hydrochloride,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2.Cl,C,"The Second AffIliated Hospital of Wenzhou 
Medical University Wenzhou, Zhejiang, China",
"A Prospective/Retrospective,Randomized Controlled Clinical Study of 
Antiviral Therapy in the 2019-nCoV Pneumonia",Oseltamivir,CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC,C,"Department and Institute of Infectious Disease
 Wuhan, Hubei, China",
"A Prospective/Retrospective,Randomized Controlled Clinical Study of 
Antiviral Therapy in the 2019-nCoV Pneumonia",Oseltamivir,CCC(CC)O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC,I,"Department and Institute of Infectious Disease
 Wuhan, Hubei, China",
TOFAcitinib in SARS-CoV2 Pneumonia,Tofacitinib,CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,C,"Ospedali Riuniti di Ancona
 Ancona, Marche, Italy",
TOFAcitinib in SARS-CoV2 Pneumonia,Tofacitinib,C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N,I,"Ospedali Riuniti di Ancona
 Ancona, Marche, Italy",
"Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia
 With Fuzheng Huayu",N-acetylcysteine,CC(=O)NC(CS)C(=O)O,C,"Shuguang Hospital
 Shanghai, Shanghai, China",
"Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia
 With Fuzheng Huayu",N-acetylcysteine,CC(=O)N[C@@H](CS)C(=O)O,I,"Shuguang Hospital
 Shanghai, Shanghai, China",
The Impact of Camostat Mesilate on COVID-19 Infection,Camostat Mesilate,CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O,C,"Department of Infectious Diseases
 Aalborg, Denmark",
Losartan for Patients With COVID-19 Requiring Hospitalization,Losartan,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,C,"Hennepin County Medical Center
 Minneapolis, Minnesota, United States",
Trial of Treatments for COVID-19 in Hospitalized Adults,Interferon Beta,C1=CN(C(=O)N=C1N)C2C(C(C(O2)COP(=O)(O)O)OP(=O)(O)OCC3C(C(C(O3)N4C=CC(=NC4=O)N)O)OP(=O)(O)OCC5C(C(C(O5)N6C=CC(=NC6=O)N)O)OP(=O)(O)OCC7C(C(C(O7)N8C=CC(=NC8=O)N)O)OP(=O)(O)OCC9C(C(C(O9)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=NC1=O)N)O)OP(=O)(O)OCC1C(C(C(O1)N1C=CC(=O)NC1=O)O)O)O.C1=NC2=C(C(=O)N1)N=CN2C3C(C(C(O3)COP(=O)(O)OC4C(OC(C4O)N5C=NC6=C5N=CNC6=O)COP(=O)(O)OC7C(OC(C7O)N8C=NC9=C8N=CNC9=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)OC1C(OC(C1O)N1C=NC2=C1N=CNC2=O)COP(=O)(O)O)O)O,C,"CHRU Lille
 Lille, France
 CHU Nantes
 Nantes, France",
"Clinical Study of Arbidol Hydrochloride Tablets in the Treatment 
of Pneumonia Caused by Novel Coronavirus",Arbidol,CCOC(=O)C1=C(N(C2=CC(=C(C(=C21)CN(C)C)O)Br)C)CSC3=CC=CC=C3,C,,
Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,Aviptadil,CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CNC=N4)N,C,"Research Center
 New York, New York, United States",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Hydrocortisone,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Ceftriaxone,CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Moxifloxacin,COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Moxifloxacin,COC1=C2C(=CC(=C1N3C[C@@H]4CCCN[C@@H]4C3)F)C(=O)C(=CN2C5CC5)C(=O)O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-].CC(=O)O.O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Ceftaroline,CCON=C(C1=NSC(=N1)NP(=O)(O)O)C(=O)NC2C3N(C2=O)C(=C(CS3)SC4=NC(=CS4)C5=CC=[N+](C=C5)C)C(=O)[O-].CC(=O)O.O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=CC=C2)C(=O)NC3C4N(C3=O)C(C(S4)(C)C)C(=O)O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Piperacillin,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Macrolide,CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)(C)OC)C)C)OC)(NC(=O)O2)O,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Macrolide,CC1C2CC(C(/C=C/C=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)(C)OC)C)C)OC)(NC(=O)O2)O,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Amoxicillin,CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C,C,"Wollongong Hospital
 Sidney, New South Wales, Australia",
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for 
Community- Acquired Pneumonia",Amoxicillin,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,I,"Wollongong Hospital
 Sidney, New South Wales, Australia",
Escin in Patients With Covid-19 Infection,Escin,CC=C(C)C(=O)OC1C(C2(C(CC1(C)C)C3=CCC4C5(CCC(C(C5CCC4(C3(CC2O)C)C)(C)CO)OC6C(C(C(C(O6)C(=O)O)OC7C(C(C(C(O7)CO)O)O)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)CO)OC(=O)C,C,"Luca Gallelli
 Catanzaro, Italy",
Escin in Patients With Covid-19 Infection,Escin,C/C=C(/C)\C(=O)O[C@@H]1[C@@H]([C@@]2([C@@H](C[C@@]3(C(=CCC4[C@]3(CCC5[C@@]4(CC[C@@H]([C@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)C)C)C2CC1(C)C)C)O)CO)OC(=O)C,I,"Luca Gallelli
 Catanzaro, Italy",
Coronavirus ACEi/ARB Investigation,Thiazide,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,C,"University Hospital Galway
 Galway, Ireland",
"COVIDL1: A Study to Investigate the Efficacy of Tradipitant in
 Treating Severe or Critical COVID-19 Infection",Tradipitant,C1=CC=C(C(=C1)C(=O)C2=C(N=CC=C2)C3=C(N(N=N3)CC4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F)C5=CC=NC=C5)Cl,C,,
"Efficacy and Safety of Darunavir and Cobicistat for Treatment
 of Pneumonia Caused by 2019-nCoV",Darunavir,CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,C,"Shanghai Public Health Clinical Center
 Shanghai, Shanghai, China",
"Efficacy and Safety of Darunavir and Cobicistat for Treatment
 of Pneumonia Caused by 2019-nCoV",Darunavir,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N,I,"Shanghai Public Health Clinical Center
 Shanghai, Shanghai, China",
"Efficacy and Safety of Darunavir and Cobicistat for Treatment
 of Pneumonia Caused by 2019-nCoV",Cobicistat,CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,C,"Shanghai Public Health Clinical Center
 Shanghai, Shanghai, China",
"Efficacy and Safety of Darunavir and Cobicistat for Treatment
 of Pneumonia Caused by 2019-nCoV",Cobicistat,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5,I,"Shanghai Public Health Clinical Center
 Shanghai, Shanghai, China",
"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination 
for nCoV Treatment",Ribavirin,C1=NC(=NN1C2C(C(C(O2)CO)O)O)C(=O)N,C,"University of Hong Kong, Queen Mary Hospital
 Hong Kong, Hong Kon",
"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination 
for nCoV Treatment",Ribavirin,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,I,"University of Hong Kong, Queen Mary Hospital
 Hong Kong, Hong Kon",
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Abemaciclib,CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",amodiaquine dihydrochloride,CCNCC1=C(C=CC(=C1)NC2=C3C=CC(=CC3=NC=C2)Cl)O.Cl.Cl,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Anidulafungin,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)O)O,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Anidulafungin,CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O,I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Bazedoxifene,CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Berbamine hydrochloride,"CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Berbamine hydrochloride,"CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)O)OC.Cl
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Cepharanthine,CN1CCC2=CC3=C(C4=C2C1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)CC7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Cepharanthine,"CN1CCC2=CC3=C(C4=C2[C@@H]1CC5=CC=C(C=C5)OC6=C(C=CC(=C6)C[C@@H]7C8=CC(=C(C=C8CCN7C)OC)O4)OC)OCO3
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Chloroquine diphosphate,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ciclesonide,CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ciclesonide,CC(C)C(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3CCC5=CC(=O)C=C[C@]45C)O)C)O[C@H](O2)C6CCCCC6,I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Clomiphene citrate,"CCN(CC)CCOC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Clomiphene citrate,"CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\Cl)/C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Cyclosporine,"CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Cyclosporine,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Digitoxin,"CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CCC7C8=CC(=O)OC8)O)C)C)C)C)O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Digitoxin,"C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Digoxin,"CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Digoxin,"C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Droloxifene,CCC(=C(C1=CC=C(C=C1)OCCN(C)C)C2=CC(=CC=C2)O)C3=CC=CC=C3,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Droloxifene,"CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\C2=CC(=CC=C2)O)/C3=CC=CC=C3
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Dronedarone HCl,"CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ebastine,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Gilteritinib,"CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Hexachlorophene,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Isoosajin,"CC1(CCC2=C3C(=C4C(=C2O1)C(=O)C(=CO4)C5=CC=C(C=C5)O)C=CC(O3)(C)C)C
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Isopomiferin,"CC1(CCC2=C3C(=C4C(=C2O1)C(=O)C(=CO4)C5=CC(=C(C=C5)O)O)C=CC(O3)(C)C)C
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ivacaftor,"CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Lanatoside C ,"CC1C(C(CC(O1)OC2CCC3(C(C2)CCC4C3CC(C5(C4(CCC5C6=CC(=O)OC6)O)C)O)C)O)OC7CC(C(C(O7)C)OC8CC(C(C(O8)C)OC9C(C(C(C(O9)CO)O)O)O)OC(=O)C)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Lanatoside C ,"C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)OC(=O)C)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ceritinib (LDK378),CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Loperamide
hydrochloride ","CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Lusutrombopag,"CCCCCCOC(C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)C=C(C)C(=O)O)Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Lusutrombopag,"CCCCCCO[C@@H](C)C1=CC=CC(=C1OC)C2=CSC(=N2)NC(=O)C3=CC(=C(C(=C3)Cl)/C=C(\C)/C(=O)O)Cl
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Mefloquine,"C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Mefloquine,"C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Mequitazine,"C1CN2CCC1C(C2)CN3C4=CC=CC=C4SC5=CC=CC=C53
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Niclosamide,"C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Osajin,"CC(=CCC1=C2C(=C3C(=C1O)C(=O)C(=CO3)C4=CC=C(C=C4)O)C=CC(O2)(C)C)C
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Osimertinib
mesylate ","CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ouabain,"CC1C(C(C(C(O1)OC2CC(C3(C4C(CCC3(C2)O)C5(CCC(C5(CC4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Ouabain,"C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Oxyclozanide,"C1=C(C=C(C(=C1NC(=O)C2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl)Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Penfluridol,"C1CN(CCC1(C2=CC(=C(C=C2)Cl)C(F)(F)F)O)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Perhexiline
maleate ","C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3.C(=CC(=O)O)C(=O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Perhexiline
maleate ","C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3.C(=C\C(=O)O)\C(=O)O
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Phenazopyridine hydrochloride,"C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Proscillaridin,"CC1C(C(C(C(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Proscillaridin,"C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O

",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Pyronaridine
tetraphosphate ","COC1=NC2=C(C3=C(C=C(C=C3)Cl)N=C2C=C1)NC4=CC(=C(C(=C4)CN5CCCC5)O)CN6CCCC6.OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O.OP(=O)(O)O
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Quinacrine
hydrochloride ","CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC.Cl.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Salinomycin sodium,CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)[O-].[Na+],C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Salinomycin sodium,"CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)[O-].[Na+]
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Tetrandrine,CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC,C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Tetrandrine,"CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)C[C@H]6C7=C(O3)C(=C(C=C7CCN6C)OC)OC)OC)OC
",I,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf","Thioridazine
hydrochloride ","CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Tilorone,"CCN(CC)CCOC1=CC2=C(C=C1)C3=C(C2=O)C=C(C=C3)OCCN(CC)CC
",C,,
"Antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full.pdf",Triparanol,"CCN(CC)CCOC1=CC=C(C=C1)C(CC2=CC=C(C=C2)Cl)(C3=CC=C(C=C3)C)O
",C,,
Negative control smiles,Fluphenazine,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,C,,
Negative control smiles,Aspirin,,C,,
Negative control smiles,Propranolol hydrochloride,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O.Cl,C,,
Negative control smiles,Carvedilol,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,C,,
Negative control smiles,deferoxamine,CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O,C,,
Negative control smiles,Secnidazole,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],C,,
Negative control smiles,GERANIOL,CC(=CCCC(=CCO)C)C,C,,
Negative control smiles,GERANIOL,CC(=CCC/C(=C/CO)/C)C,I,,
Negative control smiles,Fertirelin,CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6,C,,
Negative control smiles,Fertirelin,CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6,I,,
Negative control smiles,Tesaglitazar,CCOC(CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O,C,,
Negative control smiles,Tesaglitazar,CCO[C@@H](CC1=CC=C(C=C1)OCCC2=CC=C(C=C2)OS(=O)(=O)C)C(=O)O,I,,
Negative control smiles,Desloratadine,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,C,,
Negative control smiles,Desvenlafaxine,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,C,,
Negative control smiles,Dexrazoxane,CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,C,,
Negative control smiles,Dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,I,,
Negative control smiles,dexlansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,C,,
Negative control smiles,dexlansoprazole,CC1=C(C=CN=C1C[S@@](=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,I,,
Negative control smiles,Dexanabinol,CCCCCCC(C)(C)C1=CC(=C2C3CC(=CCC3C(OC2=C1)(C)C)CO)O,C,,
Negative control smiles,Dexanabinol,CCCCCCC(C)(C)C1=CC(=C2[C@H]3CC(=CC[C@@H]3C(OC2=C1)(C)C)CO)O,I,,
Negative control smiles,Fecosterol,CC(C)C(=C)CCC(C)C1CCC2C1(CCC3=C2CCC4C3(CCC(C4)O)C)C,C,,
Negative control smiles,Fecosterol,C[C@H](CCC(=C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4)O)C)C,I,,
Negative control smiles,Feclobuzone,CCCCC1(C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)COC(=O)C4=CC=C(C=C4)Cl,C,,
Negative control smiles,Feclemine,CCN(CC)CC(CN(CC)CC)C(C1CCCCC1)C2=CC=CC=C2,C,,
Negative control smiles,Dichlorvos,COP(=O)(OC)OC=C(Cl)Cl,,,
Negative control smiles,Dermorphin,CC(C(=O)NC(CC1=CC=CC=C1)C(=O)NCC(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)NC(CO)C(=O)N)NC(=O)C(CC4=CC=C(C=C4)O)N,C,,
Negative control smiles,Dermorphin,C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)O)N,I,,
Negative control smiles,Deramciclane,CC1(C2CCC1(C(C2)(C3=CC=CC=C3)OCCN(C)C)C)C,C,,
Negative control smiles,Deramciclane,"C[C@@]12CC[C@@H](C1(C)C)C[C@@]2(C3=CC=CC=C3)OCCN(C)C
",I,,
Negative control smiles,Deriglidole,CCCC1(CC2=CC=CC3=C2N1CC3)C4=NCCN4,C,,
Negative control smiles,derrustone,COC1=CC2=C(C(=C1)OC)C(=O)C(=CO2)C3=CC4=C(C=C3)OCO4,C,,
Negative control smiles,Lersivirine,CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N,C,,
Negative control smiles,Lercanidipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)(C)CN(C)CCC(C2=CC=CC=C2)C3=CC=CC=C3)C4=CC(=CC=C4)[N+](=O)[O-])C(=O)OC,C,,
Negative control smiles,Anileridine,CCOC(=O)C1(CCN(CC1)CCC2=CC=C(C=C2)N)C3=CC=CC=C3,C,,
Negative control smiles,Lexacalcitol,CCC(CC)(CCCOC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O,C,,
Negative control smiles,Lexacalcitol,CCC(CC)(CCCO[C@H](C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C)O,I,,
Negative control smiles,Bromazepam,C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3,C,,
Negative control smiles,hesperetin,COC1=C(C=C(C=C1)C2CC(=O)C3=C(C=C(C=C3O2)O)O)O,C,,
Negative control smiles,hesperetin,COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O)O)O,I,,
Negative control smiles,Hesperidin,CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,C,,
Negative control smiles,Hesperidin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,I,,
Negative control smiles,loratadine,"CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1

",C,,
Negative control smiles,Lornoxicam,CN1C(=C(C2=C(S1(=O)=O)C=C(S2)Cl)O)C(=O)NC3=CC=CC=N3,C,,
Negative control smiles,Lorglumide,CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl,C,,
Negative control smiles,Sertaconazole,C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl,C,,
Negative control smiles,Mephenytoin,CCC1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2,C,,
Negative control smiles,mestranol,CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)OC,C,,
Negative control smiles,mestranol,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,I,,
Negative control smiles,mesalamine,C1=CC(=C(C=C1N)C(=O)O)O,C,,
Negative control smiles,Mexiletine,CC1=C(C(=CC=C1)C)OCC(C)N,C,,
Negative control smiles,Mecillinam,CC1(C(N2C(S1)C(C2=O)N=CN3CCCCCC3)C(=O)O)C,C,,
Negative control smiles,Mecillinam,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)N=CN3CCCCCC3)C(=O)O)C,I,,
Negative control smiles,Nestoron,CC(=O)C1(C(=C)CC2C1(CCC3C2CCC4=CC(=O)CCC34)C)OC(=O)C,C,,
Negative control smiles,Nestoron,CC(=O)[C@]1(C(=C)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)OC(=O)C,I,,
Negative control smiles,Nesapidil,CC1=NN=C(O1)C2=CC(=CC=C2)OCC(CN3CCN(CC3)C4=CC=CC=C4OC)O,C,,
Negative control smiles,Thalidomide,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,C,,
Negative control smiles,Stavudine,CC1=CN(C(=O)NC1=O)C2C=CC(O2)CO,C,,
Negative control smiles,Stavudine,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,I,,
Negative control smiles,Meperidine,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2,C,,
Negative control smiles,Meperidine hydrochloride,CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2.Cl,C,,
Negative control smiles,Urethane,CCOC(=O)N,C,,
Negative control smiles,azelastine,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,C,,
Negative control smiles,4-Benzylphenol,C1=CC=C(C=C1)CC2=CC=C(C=C2)O,C,,
Negative control smiles,betaxolol,CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O,C,,
Negative control smiles,Besipirdine,CCCN(C1=CC=NC=C1)N2C=CC3=CC=CC=C32,C,,
Negative control smiles,Lesogaberan,C(C(C[P+](=O)O)F)N,C,,
Negative control smiles,Lesogaberan,C([C@H](C[P+](=O)O)F)N,I,,
Negative control smiles,Acetaldehyde,CC=O,C,,
Negative control smiles,Verbenalin,CC1CC(=O)C2C1C(OC=C2C(=O)OC)OC3C(C(C(C(O3)CO)O)O)O,C,,
Negative control smiles,Verbenalin,C[C@H]1CC(=O)[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,I,,